These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 15632376)

  • 1. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
    Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
    J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
    Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
    Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphatic regeneration: new insights from VEGFR-3 blockade.
    Aoki Y; Tosato G
    J Natl Cancer Inst; 2005 Jan; 97(1):2-3. PubMed ID: 15632367
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
    Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
    Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
    Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
    Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts.
    Nykänen AI; Sandelin H; Krebs R; Keränen MA; Tuuminen R; Kärpänen T; Wu Y; Pytowski B; Koskinen PK; Ylä-Herttuala S; Alitalo K; Lemström KB
    Circulation; 2010 Mar; 121(12):1413-22. PubMed ID: 20231530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
    Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
    Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.
    Goldman J; Rutkowski JM; Shields JD; Pasquier MC; Cui Y; Schmökel HG; Willey S; Hicklin DJ; Pytowski B; Swartz MA
    FASEB J; 2007 Apr; 21(4):1003-12. PubMed ID: 17210781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lymphangiogenes and location of tumor lymphatic vessels induced by VEGF-C in primary breast carcer].
    Huang JH; Li Y; Liu L; Yang HC; Hai J; Tang LL; Hu TH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):36-9, 51. PubMed ID: 16562672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of VEGFR-3 and 5'-nase in regenerating lymphatic vessels of the cutaneous wound healing.
    Ji RC; Miura M; Qu P; Kato S
    Microsc Res Tech; 2004 Jun; 64(3):279-86. PubMed ID: 15452895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the VEGF-C/VEGFR-3 axis in cancer progression.
    Su JL; Yen CJ; Chen PS; Chuang SE; Hong CC; Kuo IH; Chen HY; Hung MC; Kuo ML
    Br J Cancer; 2007 Feb; 96(4):541-5. PubMed ID: 17164762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
    Björndahl MA; Cao R; Burton JB; Brakenhielm E; Religa P; Galter D; Wu L; Cao Y
    Cancer Res; 2005 Oct; 65(20):9261-8. PubMed ID: 16230387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
    Veikkola T; Jussila L; Makinen T; Karpanen T; Jeltsch M; Petrova TV; Kubo H; Thurston G; McDonald DM; Achen MG; Stacker SA; Alitalo K
    EMBO J; 2001 Mar; 20(6):1223-31. PubMed ID: 11250889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
    Mylona E; Alexandrou P; Mpakali A; Giannopoulou I; Liapis G; Markaki S; Keramopoulos A; Nakopoulou L
    Eur J Surg Oncol; 2007 Apr; 33(3):294-300. PubMed ID: 17129704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
    Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
    Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
    Onofri C; Losa M; Uhl E; Stalla GK; Renner U
    Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):152-7. PubMed ID: 18205092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast.
    Li YS; Kaneko M; Amatya VJ; Takeshima Y; Arihiro K; Inai K
    Pathol Int; 2006 May; 56(5):256-61. PubMed ID: 16669874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of VEGF-C causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin.
    Goldman J; Le TX; Skobe M; Swartz MA
    Circ Res; 2005 Jun; 96(11):1193-9. PubMed ID: 15890974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGFR-3 in adult angiogenesis.
    Witmer AN; van Blijswijk BC; Dai J; Hofman P; Partanen TA; Vrensen GF; Schlingemann RO
    J Pathol; 2001 Nov; 195(4):490-7. PubMed ID: 11745682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.